These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 20930215)

  • 1. Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1.
    Thompson S; Messick T; Schultz DC; Reichman M; Lieberman PM
    J Biomol Screen; 2010 Oct; 15(9):1107-15. PubMed ID: 20930215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
    Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
    J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening.
    Li N; Thompson S; Schultz DC; Zhu W; Jiang H; Luo C; Lieberman PM
    PLoS One; 2010 Apr; 5(4):e10126. PubMed ID: 20405039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome.
    Lee EK; Kim SY; Noh KW; Joo EH; Zhao B; Kieff E; Kang MS
    Antiviral Res; 2014 Apr; 104():73-83. PubMed ID: 24486954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Basis for Cooperative Binding of EBNA1 to the Epstein-Barr Virus Dyad Symmetry Minimal Origin of Replication.
    Malecka KA; Dheekollu J; Deakyne JS; Wiedmer A; Ramirez UD; Lieberman PM; Messick TE
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31142669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth.
    Messick TE; Smith GR; Soldan SS; McDonnell ME; Deakyne JS; Malecka KA; Tolvinski L; van den Heuvel APJ; Gu BW; Cassel JA; Tran DH; Wassermann BR; Zhang Y; Velvadapu V; Zartler ER; Busson P; Reitz AB; Lieberman PM
    Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and Functional Basis for an EBNA1 Hexameric Ring in Epstein-Barr Virus Episome Maintenance.
    Deakyne JS; Malecka KA; Messick TE; Lieberman PM
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
    Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B Cell-Specific Transcription Activator PAX5 Recruits p300 To Support EBNA1-Driven Transcription.
    Liu CD; Lee HL; Peng CW
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The AT-hook DNA binding ability of the Epstein Barr virus EBNA1 protein is necessary for the maintenance of viral genomes in latently infected cells.
    Chakravorty A; Sugden B
    Virology; 2015 Oct; 484():251-258. PubMed ID: 26122471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells.
    Hong M; Murai Y; Kutsuna T; Takahashi H; Nomoto K; Cheng CM; Ishizawa S; Zhao QL; Ogawa R; Harmon BV; Tsuneyama K; Takano Y
    J Cancer Res Clin Oncol; 2006 Jan; 132(1):1-8. PubMed ID: 16180023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer.
    Mansouri S; Pan Q; Blencowe BJ; Claycomb JM; Frappier L
    J Virol; 2014 Oct; 88(19):11166-77. PubMed ID: 25031339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
    Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
    J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus.
    Tikhmyanova N; Schultz DC; Lee T; Salvino JM; Lieberman PM
    ACS Chem Biol; 2014 Mar; 9(3):785-95. PubMed ID: 24028149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.
    Dheekollu J; Malecka K; Wiedmer A; Delecluse HJ; Chiang AK; Altieri DC; Messick TE; Lieberman PM
    Oncotarget; 2017 Jan; 8(5):7248-7264. PubMed ID: 28077791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
    Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
    Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule and peptide-mediated inhibition of Epstein-Barr virus nuclear antigen 1 dimerization.
    Kim SY; Song KA; Kieff E; Kang MS
    Biochem Biophys Res Commun; 2012 Jul; 424(2):251-6. PubMed ID: 22735264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1).
    Lu F; Wikramasinghe P; Norseen J; Tsai K; Wang P; Showe L; Davuluri RV; Lieberman PM
    Virol J; 2010 Oct; 7():262. PubMed ID: 20929547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1.
    Nasimuzzaman M; Kuroda M; Dohno S; Yamamoto T; Iwatsuki K; Matsuzaki S; Mohammad R; Kumita W; Mizuguchi H; Hayakawa T; Nakamura H; Taguchi T; Wakiguchi H; Imai S
    Mol Ther; 2005 Apr; 11(4):578-90. PubMed ID: 15771960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers.
    Jiang L; Xie C; Lung HL; Lo KW; Law GL; Mak NK; Wong KL
    Theranostics; 2018; 8(19):5307-5319. PubMed ID: 30555548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.